Llwytho...
Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
Checkpoint inhibitors have become an efficient way to treat cancers. Indeed, anti-CTLA-4, anti-PD1, and anti-PDL-1 antibodies are now used as therapies for cancers. However, while these therapies are very efficient in certain tumors, they remain poorly efficient in others. This might be explained by...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | F1000Res |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
F1000 Research Limited
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7222031/ https://ncbi.nlm.nih.gov/pubmed/32489646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.22877.1 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|